Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

October 8th 2024

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

Health Canada Expands Indication for Illuccix Diagnostic Kit for PSMA-Targeted Radioligand Therapy in mCRPC

October 7th 2024

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC

October 4th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses next steps for the investigation of darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care

September 30th 2024

Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.

sNDA for Darolutamide Plus ADT in mHSPC Submitted for FDA Review

September 26th 2024

A supplemental new drug application seeking to expand the indication for darolutamide plus ADT in mHSPC has been submitted to the FDA.

Dr Saad on the Efficacy and Safety of Darolutamide Plus ADT in mHSPC

September 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy findings from the ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Dr Berchuck on Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPC

September 24th 2024

Jacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.

Rintatolimod Plus Durvalumab Shows Early Disease Control in Late-Stage Pancreatic Cancer

September 19th 2024

Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Darolutamide Plus ADT Improves rPFS in mHSPC

September 16th 2024

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

Dr D’Amico on the Nuances of a Low Gleason Score in Localized Prostate Cancer

September 10th 2024

Anthony V. D'Amico, MD, PhD, discusses Gleason score interpretation in the management of localized prostate cancer.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

September 3rd 2024

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Dr Olivares on the Functional Advantages of Focal Therapy in Prostate Cancer

August 30th 2024

Ruben Olivares, MD, discusses the functional advantages of using focal therapy over localized radiation in prostate cancer.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29th 2024

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Dr Olivares on Considerations for Managing Prostate Cancer in the Community Setting

August 29th 2024

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse Populations

August 28th 2024

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

August 27th 2024

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.